Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR 70-BCMA CAR-T Therapy for Relapsed or Refractory Plasma Cell Neoplasms
NCT07519187Phase 1Not yet recruiting
- Sponsor
- General Hospital of Western Theater Command of PLA
- Start
- Apr 2026
- Primary completion
- Apr 2027
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of C-CAR070 in plasma cell neoplasm, sponsored by General Hospital of Western Theater Command of PLA. Primary endpoints: Treatment-Emergent Adverse Events at 3 years and Maximum Tolerated Dose at 28 days. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
C-CAR070
03
Conditions
plasma cell neoplasm
Beyond the preview
Go deeper on NCT07519187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07519187.